drug for respiratory syncytial virus infection (Cidara Therapeutics)

N/A

Report date: 2025/01/26 16:16:22

Base Information

Drug Namedrug for respiratory syncytial virus infection (Cidara Therapeutics)
Drug Alias Nameantiviral Fc-conjugates for respiratory syncytial virus infection (Cloudbreak platform, ) (Cidara Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCidara Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCidara Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A